thesi updat turn bit controversi
hope hope end ilmn sequenc instrument
touch light fy growth come array
unsurprisingli disappoint get better per fy guid cut
despit nois chang helix relationship manag
kept fy revenu rang impli upsid sequenc consum
servic frankli import line model us
went underappreci ultim come thing
trust manag team compani execut flawlessli long
period deliv ramp underli sequenc demand
support pace placement inher consum
growth clearli trust manag also take bit comfort
order commentari book bill impress furthermor think
manag fair amount visibl larg custom swap out
sound like xs convert also reason view popul health
ramp sizeabl evidenc manag guid
ramp line field work furthermor everywher look
base market appear fire ex consum mix ramp
differ popseq project us hard call end clinic
upcycl frankli feel like begin go take
bit leap faith model cadenc admittedli atyp
clearli acknowledg share could trade sideway get clariti
stick long term structur winner arent get caught
short term nois reiter outperform oh way rais ep
bet eat dilut end better expect
model/pt updat estim move higher due reflect
favor implic helix deconsolid
estim tweak higher well given improv run rate
pt move higher impli price-to-earnings line level
slightli higher last year averag adjust cash hand
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
reiter growth
weight rev vs prior
mm helix revenu
nextseq pull-through rais rang
back half revenu driven sequenc system consum
nation health servic uk start scale whole-genom sequenc
growth research appli sequenc consum clinic
top-line growth
gm qoq
higher sequenc revenu driven system consum offset lower array revenu driven
servic
sequenc system ship first half
driven nipt oncolog sequenc consum
clinic sequenc continu becom signific
oncolog test applic sequenc consum shipment
genet diseas slightli less
novaseq custom expect first time order
debat point cc
array servic yoy came light vs guidanc back januari
half ramp stori call question
largest sequenc consum custom grew continu outpac total sequenc
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america
articl articl
time dissemin april
analyst luke sergott jon bristow ross muken primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research report
